Acorda Therapeutics IncOTC Pink - Current Information:ACORQ
- LAST PRICE0.9000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.9000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACORQ |
|---|---|---|
| 09:32 ET | 1000 | 0.78 |
| 09:43 ET | 1000 | 0.75 |
| 09:59 ET | 4888 | 0.75 |
| 10:30 ET | 4500 | 0.82 |
| 10:33 ET | 7100 | 0.83 |
| 10:35 ET | 5000 | 0.84 |
| 10:37 ET | 5000 | 0.85 |
| 11:18 ET | 108 | 0.8 |
| 11:45 ET | 1000 | 0.8 |
| 11:54 ET | 1000 | 0.827 |
| 01:01 ET | 1000 | 0.8 |
| 01:03 ET | 1000 | 0.8 |
| 01:28 ET | 4000 | 0.89 |
| 01:51 ET | 600 | 0.81 |
| 02:04 ET | 100 | 0.85 |
| 02:15 ET | 224 | 0.89 |
| 02:24 ET | 776 | 0.9 |
| 02:36 ET | 187 | 0.8875 |
| 02:45 ET | 591 | 0.9 |
Apr 12, 2024
*DJ News On Acorda Therapeutics Inc. (ACOR) Now Under ACORQ, from 5:08PM ET on Friday Apr 12, 2024 by Dow Jones
5:08PM ET on Friday Apr 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Acorda Therapeutics Inc | 1.1M | 0.0x | --- |
Spero Therapeutics Inc | 77.6M | 3.6x | --- |
Seres Therapeutics Inc | 137.3M | -1.0x | --- |
Rigel Pharmaceuticals Inc | 187.7M | -7.4x | --- |
CytomX Therapeutics Inc | 109.0M | -84.2x | --- |
Cannabis Bioscience International Holdings Inc | 6.7M | 0.0x | --- |
Company Information
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
Contact Information
- Headquarters
- TWO BLUE HILL PLAZAPEARL RIVER, NY, United States 10965
- Phone
- 914-347-4300
- Fax
- 914-347-4560
Executives
- Non-Executive Independent Chairman of the Board
- John Kelley
- President, Chief Executive Officer, Director
- Ron Cohen
- Chief Financial Officer
- Michael Gesser
- General Counsel, Corporate Secretary
- Neil Belloff
- Chief Commercial Officer
- Kerry Clem
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1M |
|---|---|
Revenue (TTM) | $117.6M |
Shares Outstanding | 1.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.67 |
EPS | $-203.87 |
Book Value | $-127.17 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -225.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
